

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BeiGene, Ltd.
百濟神州有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 06160)

GRANT OF SHARE OPTIONS

On December 31, 2021, the compensation committee of the Board granted the Options to subscribe for an aggregate of 4,564 ADSs to three Grantees under the 2016 Share Option and Incentive Plan.

The 2016 Share Option and Incentive Plan provides the Company with flexibility to use various equity-based incentives and other awards as compensation tools to motivate the Company's workforce.

SHARE OPTIONS UNDER THE 2016 SHARE OPTION AND INCENTIVE PLAN

On December 31, 2021, the compensation committee of the Board granted the Options to subscribe for an aggregate of 4,564 ADSs to three Grantees in accordance with the terms of the 2016 Share Option and Incentive Plan.

Details of the Grant

Pursuant to Rule 17.06A of the Listing Rules, the details of the Options are as follows:

Date of Grant: December 31, 2021

Number of Grantee(s): 3

Number of underlying Shares pursuant to the Options granted: 59,332

Number of Options granted (in ADSs): 4,564

Total number of new ADSs to be subscribed upon exercise of the Options granted: 4,564

Consideration for the grant: Nil

Exercise price of the Options granted:	US\$270.93 per ADS (approximately HK\$162.56 per ordinary share)
Validity period of the Options:	The validity period of the Options shall be ten years from the Date of Grant and the Options shall lapse at the expiry of the validity period or earlier if the service relationship has terminated prior to the expiry of the validity period.
Vesting period:	<p>The Options granted shall vest in the Grantee as follows; provided, however, that some of Options may be subject to accelerated vesting upon a termination and/or change in control:</p> <ul style="list-style-type: none"> • 25% shall vest on the first anniversary of the last trading day of the month following the Grantee's service relationship start date; and • 75% shall vest in 36 equal monthly installments following the first anniversary, in each case, subject to the Grantee's continued service relationship with the Company on such vesting dates.

The Options are subject to the terms and conditions of the 2016 Share Option and Incentive Plan and form of award agreement covering the grants.

Exercise Price

The exercise price of the Options of US\$270.93 per ADS (approximately HK\$162.56 per ordinary share) represents the higher of (i) the closing price of the ADSs of US\$270.93 per ADS (approximately HK\$162.56 per ordinary share) on the Date of Grant, and (ii) the average closing price of the ADSs of US\$267.73 per ADS (approximately HK\$160.64 per ordinary share) for the five business days immediately preceding the Date of Grant.

The Grantees are neither a Director, nor a chief executive, nor a substantial shareholder of the Company, nor an associate of any of them.

REASONS FOR AND BENEFITS OF THE GRANTS

The 2016 Share Option and Incentive Plan provides the Company with flexibility to use various equity-based incentives and other awards as compensation tools to motivate the Company's workforce.

DEFINITIONS

“2016 Share Option and Incentive Plan”	the Second Amended and Restated 2016 Share Option and Incentive Plan adopted by the Company on January 14, 2016, as amended from time to time, the principal terms of which were set out in the Company’s Proxy Statement/Circular dated April 28, 2020
“ADS(s)”	American Depositary Shares (each representing 13 ordinary shares of the Company)
“associate”	has the same meaning ascribed to it under the Listing Rules
“Board”	the board of directors of the Company
“Company”	BeiGene, Ltd., an exempted company with limited liability incorporated under the laws of the Cayman Islands on October 28, 2010 and listed on the Stock Exchange (Stock Code: 06160) and NASDAQ (Trading Symbol: BGNE)
“Date of Grant”	December 31, 2021
“Director(s)”	director(s) of the Company
“Grantee(s)”	the employee(s) of the Group who were granted Options in accordance with the 2016 Share Option and Incentive Plan on the Date of Grant
“Group”	the Company and its subsidiaries
“HK\$”	the lawful currency of Hong Kong
“Hong Kong”	Hong Kong Special Administrative Region of the PRC
“Listing Rules”	Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“NASDAQ”	The Nasdaq Global Select Market
“Option(s)”	non-qualified share option(s) to subscribe for or acquire ordinary shares (including in the form of ADSs) which are granted under the 2016 Share Option and Incentive Plan
“PRC”	the People’s Republic of China
“Share(s)”	ordinary shares in the issued capital of the Company with a nominal value of US\$0.0001

“Stock Exchange”

The Stock Exchange of Hong Kong Limited

“subsidiary(ies)”

has the same meaning ascribed to it under the Listing Rules

For the purpose of this announcement and for illustrative purpose only, conversions of US\$ to HK\$ are based on the exchange rate of US\$1.00 = HK\$7.80. No representation is made that any amounts in HK\$ or US\$ can be or could have been converted at the relevant dates at the above rate or at any other rates or at all.

By order of the Board
BeiGene, Ltd.
Mr. John V. Oyler
Chairman

Hong Kong, January 5, 2022

As at the date of this announcement, the Board of Directors of the Company comprises Mr. John V. Oyler as Chairman and Executive Director, Dr. Xiaodong Wang and Mr. Anthony C. Hooper as Non-executive Directors, and Mr. Timothy Chen, Mr. Donald W. Glazer, Mr. Michael Goller, Mr. Ranjeev Krishana, Mr. Thomas Malley, Dr. Corazon (Corsee) D. Sanders, Mr. Jing-Shyh (Sam) Su and Mr. Qingqing Yi as Independent Non-executive Directors.